Treatments
TL;DR: 9 FDA-approved drugs have labels that mention pancreatic cancer in their indications. Grouped below by mechanism of action. This list gives you the vocabulary — your oncologist chooses a regimen based on your specific subtype, stage, biomarkers, and prior therapies.
Source: OpenFDA drug label API · last checked
Cost transparency
Drugs below have published Medicare Part B or Part D spending figures — what the federal government actually paid per beneficiary in 2023.
Figures are average Medicare spending per beneficiary. Out-of-pocket varies by insurance and manufacturer assistance. See all drug costs →
Monoclonal antibodies and antibody-drug conjugates (ADCs) that bind specific proteins on cancer cells.
From the FDA label: 1 INDICATIONS AND USAGE BIZENGRI® is a bispecific HER2- and HER3-directed antibody indicated for the treatment of: Adults with advanced, unresectable or metastatic non-small cell lung cancer (NSCLC) harboring a neuregulin 1 ( NRG1 ) gene fu…
Small-molecule drugs taken by mouth that block specific molecular pathways driving cancer growth (kinases, PARP, CDK4/6, etc.).
From the FDA label: 1 INDICATIONS AND USAGE Erlotinib tablets are a kinase inhibitor indicated for: The treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon…
From the FDA label: 1 INDICATIONS AND USAGE Erlotinib tablet is a kinase inhibitor indicated for: The treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 2…
Poly(ADP-Ribose) Polymerase Inhibitor [EPC] · Poly(ADP-Ribose) Polymerase Inhibitors [MoA]
From the FDA label: 1 INDICATIONS AND USAGE Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated: Ovarian cancer • for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA -mutated adva…
Cytotoxic drugs that kill rapidly dividing cells. Includes platinums, taxanes, antimetabolites, alkylators, topoisomerase inhibitors, and anthracyclines.
Nucleoside Metabolic Inhibitor [EPC] · Nucleic Acid Synthesis Inhibitors [MoA]
From the FDA label: 1 INDICATIONS AND USAGE Capecitabine tablet is a nucleoside metabolic inhibitor indicated for: Colorectal Cancer • adjuvant treatment of patients with Stage III colon cancer as a single agent or as a component of a combination chemotherapy
Nucleoside Metabolic Inhibitor [EPC] · Nucleic Acid Synthesis Inhibitors [MoA]
From the FDA label: 1 INDICATIONS & USAGE Fluorouracil is indicated for the treatment of patients with: Fluorouracil is a nucleoside metabolic inhibitor indicated for the treatment of patients with • Adenocarcinoma of the Colon and Rectum ( 1.1 ) • Adenocarcin…
From the FDA label: 1 INDICATIONS AND USAGE Gemcitabine Injection is a nucleoside metabolic inhibitor indicated: in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-base…
From the FDA label: 1 INDICATIONS AND USAGE Gemcitabine Injection is a nucleoside metabolic inhibitor indicated: • in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-ba…
From the FDA label: 1 INDICATIONS AND USAGE ONIVYDE is indicated, in combination with oxaliplatin, fluorouracil and leucovorin for the first-line treatment of adult patients with metastatic pancreatic adenocarcinoma. ONIVYDE is indicated, in combination with f…
Disease foundations below have active funds covering pancreatic cancer medications. Manufacturer patient-assistance programs are listed on each drug's cost page.
copay, premium, and deductible assistance for insured patients; fund availability varies by disease
https://www.healthwellfoundation.org/disease-funds/Funds open and close based on availability; check disease-funds page for current status
copay assistance for 20+ cancer types via disease-specific funds
https://www.panfoundation.org/find-disease-fund/Merging with Patient Advocate Foundation; unified 'TotalAssist' program launches 2026-07-01
direct copay / coinsurance assistance via disease-specific funds
https://copays.org/Merging with PAN Foundation; launching 'TotalAssist' 2026-07-01
copay assistance for chemotherapy and targeted treatment medications
https://www.cancercare.org/copayfoundationlimited financial assistance for transportation, home care, child care, and treatment-related costs
https://www.cancercare.org/financialTrials test new therapies before they are FDA-approved. Often a way to access tomorrow's drugs today.
Back to Pancreatic Cancer hub →Stats, second opinions, NCI cancer centers, oncologists.
Understand biomarkers →Most targeted therapies require biomarker testing. Here's what you need to know.
Read your pathology report →Which drugs apply to you depends on what's in your pathology.